Though association of CALD1 to breast cancer therapy outcome has been poorly assessed so far, ANXA1 expression was previously associated to BRCA1/2 mutation carriers and prediction of high mortality risk in Her2+ patients [30]. This evidence concerns the gene ERBB2 and breast cancer.